<DOC>
	<DOCNO>NCT02809105</DOCNO>
	<brief_summary>The objective study verify efficacy investigate safety study drug ASP0456 administer orally 4 week 52 week .</brief_summary>
	<brief_title>A Study Oral Dosing ASP0456 Patients With Chronic Constipation</brief_title>
	<detailed_description>This study consist two part . In Part I , ASP0456 placebo administer orally blind manner . In Part II , long-term safety efficacy ASP0456 evaluate patient participate study complete Part I .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<criteria>Patients SBM frequency &lt; 3 times/week , since ≥ 6 month prior preliminary enrollment Patients one relate symptom ≥ 6 month prior preliminary enrollment Patients loose ( mushy ) watery stool rarely present without use laxative ≥ 6 month prior preliminary enrollment Patients underwent pancolonoscopy contrast enema development CC symptom within 5 year prior preliminary enrollment , organic change observe dose influence CC symptom Female patient must either : Be nonchildbearing potential : Postmenopausal preliminary enrollment , document surgically sterile Or , childbearing potential , Agree try become pregnant study 28 day final study drug administration And negative urine pregnancy test screening And , heterosexually active , agree consistently use two form highly effective birth control throughout study period 28 day final study drug administration Female patient must agree breastfeed throughout study period 28 day final study drug administration Female patient must donate ovum start throughout study period 28 day final study drug administration Male subject female spouse/partners childbearing potential must use two form highly effective form birth control start Screening continue throughout study period , 28 day final study drug administration Male subject must donate sperm start Screening throughout study period , 28 day final study drug administration Patients meet Rome III diagnostic criterion IBS ; recurrent abdominal pain discomfort ≥ 3 days/month last 3 month prior preliminary enrollment , associate ≥ 2 3 characteristic describe symptom ( IBS symptom ) describe ≥ 6 month prior preliminary enrollment 1 . Improvement defecation 2 . Onset associate change frequency stool 3 . Onset associate change form ( appearance ) stool Patients history surgical resection stomach , gallbladder , small intestine , large intestine Patients history current evidence inflammatory bowel disease ischemic colitis Patients concurrent infectious enteritis , hyperthyroidism hypothyroidism , constipation due anorectal dysfunction , druginduced constipation , constipation due organic disease active peptic ulcer Patients apparent mechanical obstruction Patients megacolon megarectum For female patient , patient concurrent endometriosis adenomyosis Patients consider severe depression severe anxiety disorder affect efficacy evaluation study drug Patients history abuse drug alcohol , current abuse drug alcohol Patients used/underwent schedule use/undergo prohibit concomitant drug therapy , prohibit examination conduct schedule conduct 3 day prior start bowel habit observation period Patients history current evidence malignant tumor Patients concurrent serious cardiovascular disease , respiratory disease , renal disease , hepatic disease , gastrointestinal disorder , blood disease , neurological/psychiatric disease Patients history drug allergies Patients participate clinical trial ASP0456 history ASP0456 administration Patients participate participate another clinical trial postmarketing clinical study ethical drug medical device within 12 week prior obtain inform consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Chronic constipation</keyword>
	<keyword>Linaclotide</keyword>
	<keyword>ASP0456</keyword>
</DOC>